Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

Show Description +

Dr. Do shares new 24-week data from the phase 3b ELARA study of 8 mg aflibercept (Eylea HD, Regeneron), which is exploring flexible dosing regimens in patients with wet AMD or diabetic macular edema.

Posted: 10/30/2025

Keywords:

retina-meeting-recap

•

aflibercept

•

high-dose aflibercept

•

EYLEA HD

•

Eylea

•

Regeneron

•

flexible dosing

•

ELARA

•

Clinical Trials

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Diabetic macular edema, DME

•

Retina Subspecialty Day

Up Next

Name: Flexible Dosing for High-Dose Aflibercept: The Data
Uploaded: 2025-10-30T18:03:47+00:00
Description: Dr. Do shares new 24-week data from the phase 3b ELARA study of 8 mg aflibercept (Eylea HD, Regeneron), which is exploring flexible dosing regimens in patients with wet AMD or diabetic macular edema.

Imaging and for Neurocognitive Disease

Sharon Fekrat, MD, FACS

All things Surgical at AAO

Maria H. Berrocal, MD

How to Start CTAK/CAIRS in Your Practice

Rahul Tonk, MD, MBA

Management of Neurotrophic Keratitis

Sumitra Khandelwal, MD

Update on Lasers Newly Approved in the USA

George O. Waring IV, MD, FACS

Latest Laser Technology in Oculoplastics

Arturo Balaguer Townsend

Clinical Ergonomics

Alison D. Early, MD

Epi-On Collagen Crosslinking for Keratoconus

Mitchell Weikert, MD

What Your OCT Can Tell You About Your Patient’s Systemic Health

Cecilia Lee, MD

New Tools to Help With Medication Adherence

Andrew M. Williams, MD

Improving Efficiency in the Operating Room

Manjool Shah, MD

Picking Winners: Choosing IOLs in Glaucoma Patients

Emily Schehlein, MD

Back to the Suprachoroidal Space: Lessons Learned

Shivani Kamat, MD

Next-Gen Glaucoma Self-Care and Home Monitoring

Kateki Vinod, MD

Management and Prevention of Serious Drug-Related and Toxic Complications Following Cataract Surgery

Nick Mamalis, MD

Environmental Impact of Cataract Surgery in the 21st Century

David F. Chang, MD

Phacoemulsification With Near Physiologic Versus High IOP Settings

John A. Hovanesian, MD

Angle-Based MIGS: By and for the Cataract Surgeon

Cathleen M. McCabe, MD

High-Dose Aflibercept in the Real World

Diana Do, MD

Oral Micronutrients and GA

Rishi P. Singh, MD

Imaging in the Retina OR: Today's Innovations

Katherine Talcott, MD

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

AI in Today's Retina Practice

Raymond Iezzi, MD

Back to All Videos

Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

Dr. Do shares new 24-week data from the phase 3b ELARA study of 8 mg aflibercept (Eylea HD, Regeneron), which is exploring flexible dosing regimens in patients with wet AMD or diabetic macular edema.

Posted: 10/30/2025

Keywords:

retina-meeting-recap

•

aflibercept

•

high-dose aflibercept

•

EYLEA HD

•

Eylea

•

Regeneron

•

flexible dosing

•

ELARA

•

Clinical Trials

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Diabetic macular edema, DME

•

Retina Subspecialty Day

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Flexible Dosing for High-Dose Aflibercept: The Data

Up Next

Flexible Dosing for High-Dose Aflibercept: The Data

More From AAO: 2025 Coverage